An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
I really think Parp Breast Cancer developments are getting exciting, especially the new products recently presented at ASCO, lets hope they make phase three and pass FDA regulations to be sold on the open market!
ReplyDeleteImportant to note that PARP inhibitors are in clinical trials for women with OVARIAN cancer - BRCA carriers:
ReplyDelete"...also helped ovarian cancer patients, without the need for chemotherapy."